<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CLOLAR- clofarabine injection </strong><br>sanofi-aventis U.S. LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use CLOLAR safely and effectively. See full prescribing information for CLOLAR.<br><br>Clolar<span class="Sup">®</span> (clofarabine) Injection for intravenous use<br>Initial U.S. Approval: 2004</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><table class="Noautorules" width="100%">
<col align="left" valign="top" width="85%">
<col align="left" valign="top" width="15%">
<tbody class="Headless"><tr>
<td align="left">Warnings and Precautions (<a href="#S5.2">5.2</a>, <a href="#S5.9">5.9</a>, <a href="#S5.10">5.10</a>)</td>
<td align="left">09/2014</td>
</tr></tbody>
</table></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">Clolar (clofarabine) injection is a purine nucleoside metabolic inhibitor indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory <span class="product-label-link" type="condition" conceptid="134305" conceptname="Acute lymphoid leukemia">acute lymphoblastic leukemia</span> after at least two prior regimens. This indication is based upon response rate. There are no trials verifying an improvement in disease-related symptoms or increased survival with Clolar. (<a href="#S1">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>Administer the recommended pediatric dose of 52 mg/m<span class="Sup">2</span> as an intravenous infusion over 2 hours daily for 5 consecutive days of a 28-day cycle. Repeat cycles every 2–6 weeks. (<a href="#S2.1">2.1</a>)</li>
<li>Provide supportive care, such as intravenous infusion fluids, antihyperuricemic treatment, and alkalinization of urine throughout the 5 days of Clolar administration to reduce the risk of tumor lysis and other adverse events. (<a href="#S2.1">2.1</a>)</li>
<li>Discontinue Clolar if <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> develops during the 5 days of administration. (<a href="#S2.1">2.1</a>)</li>
<li>Reduce the dose in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. (<a href="#S2.1">2.1</a>)</li>
<li>Use dose modification for toxicity. (<a href="#S2.3">2.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul><li>20 mg/20 mL single-use vial. (<a href="#S3">3</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul><li>None. (<a href="#S4">4</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li><span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span>:  May be severe and prolonged.  Monitor complete blood counts and platelet counts during Clolar therapy. (<a href="#S5.1">5.1</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span>: Serious and fatal cerebral, gastrointestinal and <span class="product-label-link" type="condition" conceptid="4301606" conceptname="Pulmonary hemorrhage">pulmonary hemorrhage</span>. Monitor platelets and coagulation parameters and treat accordingly. (<a href="#S5.2">5.2</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>: Severe and fatal <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> as a result of bone marrow suppression.  Monitor for signs and symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>; discontinue Clolar and treat promptly. (<a href="#S5.3">5.3</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">Tumor Lysis syndrome</span>: Anticipate, monitor for signs and symptoms and treat promptly. <a href="#S5.4">(5.4</a>) </li>
<li><span class="product-label-link" type="condition" conceptid="434821" conceptname="Systemic inflammatory response syndrome">Systemic Inflammatory Response Syndrome</span> (<span class="product-label-link" type="condition" conceptid="434821" conceptname="Systemic inflammatory response syndrome">SIRS</span>) or <span class="product-label-link" type="condition" conceptid="4227747" conceptname="Capillary leak syndrome">Capillary Leak Syndrome</span>: Monitor for and discontinue Clolar immediately if suspected. (<a href="#S5.5">5.5</a>)</li>
<li>Venous Occlusive Disease of the Liver: Monitor for and discontinue Clolar if suspected. (<a href="#S5.6">5.6</a>)</li>
<li>Hepatotoxicity: Severe and fatal hepatotoxicity.  Monitor liver enzymes and discontinue Clolar. (<a href="#S5.7">5.7</a>)</li>
<li>Renal Toxicity: Increased creatinine and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>; monitor renal function and interrupt or discontinue Clolar. (<a href="#S5.8">5.8</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">Enterocolitis</span>: Serious and fatal <span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">enterocolitis</span>, occurring more frequently within 30 days of treatment and with combination chemotherapy. Monitor patients for signs and symptoms of <span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">enterocolitis</span> and treat promptly (<a href="#S5.9">5.9</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span>: <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> (SJS) and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (TEN), including fatal cases. Discontinue for exfoliative or <span class="product-label-link" type="condition" conceptid="4032934" conceptname="Vesiculobullous rash">bullous rash</span>, or if SJS or TEN is suspected. (<a href="#S5.10">5.10</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (≥ 10%): <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, palmar-plantar erythrodysesthesia syndrome, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, and <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucosal inflammation</span>. (<a href="#S6">6</a>) </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Genzyme Corporation at 1-800-RX-CLOLAR or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div><div></div></div>
<div></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul>
<li>Safety and effectiveness have not been established in adults. (<a href="#S8.6">8.6</a>)</li>
<li>Embryo-fetal Toxicity: fetal harm can occur when administered to a pregnant woman.  Women should be advised to avoid becoming pregnant when receiving Clolar. (<a href="#S5.8">5.8</a>, <a href="#S8.1">8.1</a>)</li>
</ul></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div><div></div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 9/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1. INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2. DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1  Recommended Dosage</a></h2>
<h2><a href="#section-2.2" class="toc">2.2	Supportive Medications and Medications to Avoid</a></h2>
<h2><a href="#section-2.3" class="toc">2.3	Dose Modifications and Reinitiation of Therapy</a></h2>
<h2><a href="#section-2.4" class="toc">2.4	Reconstitution/Preparation</a></h2>
<h2><a href="#section-2.5" class="toc">2.5	Incompatibilities</a></h2>
<h1><a href="#section-3" class="toc">3. DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4. CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5. WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1	<span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2	<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span> </a></h2>
<h2><a href="#section-5.3" class="toc">5.3	<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4	<span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">Hyperuricemia</span> (Tumor Lysis)</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 	<span class="product-label-link" type="condition" conceptid="434821" conceptname="Systemic inflammatory response syndrome">Systemic Inflammatory Response Syndrome</span> (<span class="product-label-link" type="condition" conceptid="434821" conceptname="Systemic inflammatory response syndrome">SIRS</span>) and <span class="product-label-link" type="condition" conceptid="4227747" conceptname="Capillary leak syndrome">Capillary Leak Syndrome</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 	Venous Occlusive Disease of the Liver</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 	Hepatotoxicity</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 	Renal Toxicity</a></h2>
<h2><a href="#section-5.9" class="toc">5.9 	<span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">Enterocolitis</span></a></h2>
<h2><a href="#section-5.10" class="toc">5.10 	<span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></a></h2>
<h2><a href="#section-5.11" class="toc">5.11	Embryo-fetal Toxicity</a></h2>
<h1><a href="#section-6" class="toc">6. ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1	Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2	Post-marketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7. DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8. USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6	Adults with Hematologic Malignancies</a></h2>
<h2><a href="#section-8.6" class="toc">8.7 	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.8 	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10. OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11. DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12. CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13. NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14. CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">15. REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16. HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17. PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1. INDICATIONS AND USAGE</h1>
<p class="First">Clolar<span class="Sup">®</span> (clofarabine) Injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory <span class="product-label-link" type="condition" conceptid="134305" conceptname="Acute lymphoid leukemia">acute lymphoblastic leukemia</span> after at least two prior regimens. This indication is based upon response rate. There are no trials verifying an improvement in disease-related symptoms or increased survival with Clolar.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2. DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1  Recommended Dosage</h2>
<p class="First">Administer the recommended pediatric dose of 52 mg/m<span class="Sup">2</span> as an intravenous infusion over 2 hours daily for 5 consecutive days.</p>
<ul class="Disc">
<li>Treatment cycles are repeated following recovery or return to baseline organ function, approximately every 2 to 6 weeks. The dosage is based on the patient's body surface area (BSA), calculated using the actual height and weight before the start of each cycle. To prevent drug incompatibilities, no other medications should be administered through the same intravenous line.</li>
<li>Provide supportive care, such as intravenous fluids, antihyperuricemic treatment, and alkalinize urine throughout the 5 days of Clolar administration to reduce the effects of tumor lysis and other adverse events.</li>
<li>Discontinue Clolar if <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> develops during the 5 days of administration.</li>
<li>Monitor renal and hepatic function during the 5 days of Clolar administration [see <span class="Italics"><a href="#S5.6">Warnings and Precautions (5.6</a>, <a href="#S5.7">5.7)</a></span>].</li>
<li>Monitor patients taking medications known to affect blood pressure. Monitor cardiac function during administration of Clolar.</li>
<li>										Reduce the dose by 50% in patients with creatinine clearance (CrCL) between 30 and 60 mL/min. There is insufficient information to make a dosage recommendation in patients with CrCL less than 30 mL/min [see <span class="Italics"><a href="#S8.7">Use in Specific Populations (8.7)</a></span>]. 									</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2	Supportive Medications and Medications to Avoid</h2>
<ul>
<li>Consider <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> anti-emetic medications as Clolar is moderately emetogenic.</li>
<li>Consider the use of <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> steroids to mitigate <span class="product-label-link" type="condition" conceptid="434821" conceptname="Systemic inflammatory response syndrome">Systemic Inflammatory Response Syndrome</span> (<span class="product-label-link" type="condition" conceptid="434821" conceptname="Systemic inflammatory response syndrome">SIRS</span>) or <span class="product-label-link" type="condition" conceptid="4227747" conceptname="Capillary leak syndrome">capillary leak syndrome</span> (e.g., <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">tachypnea</span>, and <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>).</li>
<li>										Minimize exposure to drugs with known renal toxicity during the 5 days of Clolar administration since the risk of renal toxicity may be increased. 									</li>
<li>Consider avoiding concomitant use of medications known to induce hepatic toxicity.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3	Dose Modifications and Reinitiation of Therapy</h2>
<ul>
<li>Hematologic Toxicity <ul class="Disc">
<li>Administer subsequent cycles no sooner than 14 days from the starting day of the previous cycle and provided the patient's ANC is ≥ 0.75 × 10<span class="Sup">9</span>/L.</li>
<li>If a patient experiences a Grade 4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (ANC &lt;0.5 × 10<span class="Sup">9</span>/L) lasting ≥4 weeks, reduce dose by 25% for the next cycle.</li>
</ul>
</li>
<li>Non-hematologic Toxicity <ul class="Disc">
<li>Withhold Clolar if a patient develops a clinically significant <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, until the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is controlled, then restart at the full dose.</li>
<li>Withhold Clolar for a Grade 3 non-infectious non-hematologic toxicity (excluding transient elevations in serum transaminases and/or serum bilirubin and/or <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> controlled by antiemetic therapy). Re-institute Clolar administration at a 25% dose reduction when resolution or return to baseline.</li>
<li>Discontinue Clolar administration for a Grade 4 non-infectious non-hematologic toxicity.</li>
<li>Discontinue Clolar administration if a patient shows early signs or symptoms of <span class="product-label-link" type="condition" conceptid="434821" conceptname="Systemic inflammatory response syndrome">SIRS</span> or capillary leak (e.g., <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">tachypnea</span>, and <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>) occur and provide appropriate supportive measures.</li>
<li>Discontinue Clolar administration if Grade 3 or higher increases in creatinine or bilirubin are noted. Re-institute Clolar with a 25% dose reduction, when the patient is stable and organ function has returned to baseline. If <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span> is anticipated (tumor lysis), initiate measures to control uric acid. 											</li>
</ul>
</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.4"></a><a name="section-2.4"></a><p></p>
<h2>2.4	Reconstitution/Preparation</h2>
<p class="First">Clolar should be filtered through a sterile 0.2 micron syringe filter and then diluted with 5% Dextrose Injection, USP, or 0.9% Sodium Chloride Injection, USP, prior to intravenous (IV) infusion to a final concentration between 0.15 mg/mL and 0.4 mg/mL. Use within 24 hours of preparation. Store diluted Clolar at room temperature (15–30ºC).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.5"></a><a name="section-2.5"></a><p></p>
<h2>2.5	Incompatibilities</h2>
<p class="First">Do not administer any other medications through the same intravenous line.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3. DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">20 mg/20 mL (1 mg/mL) single-use vial</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4. CONTRAINDICATIONS</h1>
<p class="First">None</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5. WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1	<span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span></h2>
<p class="First">Clolar causes <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> which may be severe and prolonged.  <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">Febrile neutropenia</span> occurred in 55% and non-<span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span> in an additional 10% of pediatric patients in clinical trials.  At initiation of treatment, most patients in the clinical studies had hematological impairment as a manifestation of <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span>. <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span> is usually reversible with interruption of Clolar treatment and appears to be dose-dependent.  Monitor complete blood counts [see <span class="Italics"><a href="#S2.3">Dosage and Administration (2.3)</a></span>]. 								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2	<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span> </h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Serious and fatal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, including cerebral, gastrointestinal and <span class="product-label-link" type="condition" conceptid="4301606" conceptname="Pulmonary hemorrhage">pulmonary hemorrhage</span>, has occurred. The majority of the cases were associated with <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>. Monitor platelets and coagulation parameters and treat accordingly [see <span class="Italics"><a href="#S6.2">Adverse Reactions (6.2)</a></span>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3	<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h2>
<p class="First">									Clolar increases the risk of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, including severe and fatal <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, and <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>. At baseline, 48% of the pediatric patients had one or more concurrent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. A total of 83% of patients experienced at least one <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> after Clolar treatment, including fungal, viral and <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. Monitor patients for signs and symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, discontinue Clolar, and treat promptly. 								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4	<span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">Hyperuricemia</span> (Tumor Lysis)</h2>
<p class="First">									Administration of Clolar may result in <span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">tumor lysis syndrome</span> associated with the break-down metabolic products from peripheral <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> <span class="product-label-link" type="condition" conceptid="4034461" conceptname="Cytolysis">cell death</span>. Monitor patients undergoing treatment for signs and symptoms of <span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">tumor lysis syndrome</span> and initiate preventive measures including adequate intravenous fluids and measures to control uric acid. 								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5 	<span class="product-label-link" type="condition" conceptid="434821" conceptname="Systemic inflammatory response syndrome">Systemic Inflammatory Response Syndrome</span> (<span class="product-label-link" type="condition" conceptid="434821" conceptname="Systemic inflammatory response syndrome">SIRS</span>) and <span class="product-label-link" type="condition" conceptid="4227747" conceptname="Capillary leak syndrome">Capillary Leak Syndrome</span></h2>
<p class="First">									Clolar may cause a cytokine release syndrome (e.g., <span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">tachypnea</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>) that may progress to the <span class="product-label-link" type="condition" conceptid="434821" conceptname="Systemic inflammatory response syndrome">systemic inflammatory response syndrome</span> (<span class="product-label-link" type="condition" conceptid="434821" conceptname="Systemic inflammatory response syndrome">SIRS</span>) with <span class="product-label-link" type="condition" conceptid="4227747" conceptname="Capillary leak syndrome">capillary leak syndrome</span> and organ impairment which may be fatal. Monitor patients frequently for these conditions. In clinical trials, <span class="product-label-link" type="condition" conceptid="434821" conceptname="Systemic inflammatory response syndrome">SIRS</span> was reported in two patients (2%); <span class="product-label-link" type="condition" conceptid="4227747" conceptname="Capillary leak syndrome">capillary leak syndrome</span> was reported in four patients (4%). Symptoms included rapid onset of <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, pleural and <span class="product-label-link" type="condition" conceptid="4161701" conceptname="Pericardial effusion">pericardial effusion</span>, and multi-organ failure. Close monitoring for this syndrome and early intervention may reduce the risk. Immediately discontinue Clolar and provide appropriate supportive measures. The use of <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> steroids (e.g., 100 mg/m<span class="Sup">2</span> hydrocortisone on Days 1 through 3) may be of benefit in preventing signs or symptoms of <span class="product-label-link" type="condition" conceptid="434821" conceptname="Systemic inflammatory response syndrome">SIRS</span> or capillary leak. Consider use of diuretics and/or albumin. After the patient is stabilized and organ function has returned to baseline, re-treatment with Clolar can be considered with a 25% dose reduction. 								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6 	Venous Occlusive Disease of the Liver</h2>
<p class="First">									Patients who have previously received a hematopoietic stem cell transplant (HSCT) are at higher risk for veno-occlusive disease (VOD) of the liver following treatment with clofarabine (40 mg/m<span class="Sup">2</span>) when used in combination with etoposide (100 mg/m<span class="Sup">2</span>) and cyclophosphamide (440 mg/m<span class="Sup">2</span>). Severe hepatotoxic events have been reported in a combination study of clofarabine in pediatric patients with relapsed or refractory <span class="product-label-link" type="condition" conceptid="138708" conceptname="Acute leukemia">acute leukemia</span>. Two cases (2%) of VOD in the mono-therapy studies were considered related to study drug. Monitor for and discontinue Clolar if VOD is suspected. 								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7 	Hepatotoxicity</h2>
<p class="First">									Severe and fatal hepatotoxicity has occurred with the use of Clolar. In clinical studies, Grade 3–4 liver enzyme elevations were observed in pediatric patients during treatment with Clolar at the following rates: elevated <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> (AST) occurred in 36% of patients; elevated <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> (ALT) occurred in 44% of patients. AST and ALT elevations typically occurred within 10 days of Clolar administration and returned to Grade 2 or less within 15 days. Grade 3 or 4 elevated bilirubin occurred in 13% of patients, with 2 events reported as Grade 4 <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span> (2%), one of which resulted in treatment discontinuation and one patient had multi-organ failure and died. Eight patients (7%) had Grade 3 or 4 elevations in serum bilirubin at the last time point measured; these patients died due to <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> and/or multi-organ failure. Monitor hepatic function and discontinue Clolar for Grade 3 or greater liver enzyme elevations [see <span class="Italics"><a href="#S6.1">Adverse Reactions (6.1)</a></span>]. 								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.8"></a><a name="section-5.8"></a><p></p>
<h2>5.8 	Renal Toxicity</h2>
<p class="First">									In clinical studies, Grade 3 or 4 elevated creatinine occurred in 8% of patients; <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> was reported as Grade 3 in three patients (3%) and Grade 4 in two patients (2%). <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">Hematuria</span> was observed in 13% of patients overall. Monitor patients for renal toxicity and interrupt or discontinue Clolar as necessary. 								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.9"></a><a name="section-5.9"></a><p></p>
<h2>5.9 	<span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">Enterocolitis</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Fatal and serious cases of <span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">enterocolitis</span>, including <span class="product-label-link" type="condition" conceptid="4342664" conceptname="Neutropenic colitis">neutropenic colitis</span>, <span class="product-label-link" type="condition" conceptid="4189378" conceptname="Typhlitis">cecitis</span>, and C. difficile <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, have occurred during treatment with clofarabine. This has occurred more frequently within 30 days of treatment, and in the setting of combination chemotherapy. <span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">Enterocolitis</span> may lead to <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>, perforation, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> or <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> complications . Monitor patients for signs and symptoms of <span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">enterocolitis</span> and treat promptly [see <span class="Italics"><a href="#S6.2">Adverse Reactions (6.2</a>)</span>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.10"></a><a name="section-5.10"></a><p></p>
<h2>5.10 	<span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Serious and fatal cases of <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> (SJS) and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (TEN), have been reported. Discontinue Clofarabine for exfoliative or <span class="product-label-link" type="condition" conceptid="4032934" conceptname="Vesiculobullous rash">bullous rash</span>, or if SJS or TEN is suspected [see <span class="Italics"><a href="#S6.2">Adverse Reactions (6.2)</a></span>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.11"></a><a name="section-5.11"></a><p></p>
<h2>5.11	Embryo-fetal Toxicity</h2>
<p class="First">Clolar can cause fetal harm when administered to a pregnant woman.  Intravenous doses of clofarabine in rats and rabbits administered during organogenesis caused an increase in resorptions, malformations, and variations [see <span class="Italics"><a href="#S8.1">Use in Specific Populations (8.1)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6. ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are discussed in greater detail in other sections of the label:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span> [see <span class="Italics"><a href="#S5.1">Warnings and Precautions (5.1)</a></span>]</li>
<li><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span> [see <span class="Italics"><a href="#S5.2">Warnings and Precautions (5.2)</a></span>]</li>
<li>Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> [see <span class="Italics"><a href="#S5.3">Warnings and Precautions (5.3)</a></span>] 							</li>
<li><span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">Hyperuricemia</span> (Tumor Lysis) [see <span class="Italics"><a href="#S5.4">Warnings and Precautions (5.4)</a></span>]</li>
<li><span class="product-label-link" type="condition" conceptid="434821" conceptname="Systemic inflammatory response syndrome">Systemic Inflammatory Response Syndrome</span> (<span class="product-label-link" type="condition" conceptid="434821" conceptname="Systemic inflammatory response syndrome">SIRS</span>) and <span class="product-label-link" type="condition" conceptid="4227747" conceptname="Capillary leak syndrome">Capillary Leak Syndrome</span> [see <span class="Italics"><a href="#S5.5">Warnings and Precautions (5.5)</a></span>]</li>
<li>Venous Occlusive Disease of the Liver [<span class="Italics">see <a href="#S5.6">Warnings and Precautions (5.6)</a></span>]</li>
<li>Hepatotoxicity [<span class="Italics">see <a href="#S5.7">Warnings and Precautions (5.7)</a></span>]</li>
<li>Renal Toxicity [<span class="Italics">see <a href="#S5.8">Warnings and Precautions (5.8)</a></span>]</li>
<li><span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">Enterocolitis</span> [<span class="Italics">see <a href="#S5.9">Warnings and Precautions (5.9)</a></span>]</li>
<li><span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span> [<span class="Italics">see 									<a href="#S5.10">Warnings and Precautions (5.10)</a></span>]</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1	Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>The data described below reflect exposure to Clolar in 115 pediatric patients with relapsed or refractory <span class="product-label-link" type="condition" conceptid="134305" conceptname="Acute lymphoid leukemia">Acute Lymphoblastic Leukemia</span> (ALL) (70 patients) or Acute Myelogenous <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">Leukemia</span> (AML) (45 patients).</p>
<p>In total, 115 pediatric patients treated in clinical trials received the recommended dose of Clolar 52 mg/m<span class="Sup">2</span> daily × 5. The median number of cycles was 2. The median cumulative amount of Clolar received by pediatric patients during all cycles was 540 mg.</p>
<p>The most common adverse reactions occurring in 10% or more of patients treated with Clolar are: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, palmar-plantar erythrodysesthesia syndrome, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, and <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucosal inflammation</span>.</p>
<p>Table 1 lists adverse reactions by System Organ Class, including severe or life-threatening (NCI CTC Grade 3 or Grade 4), reported in ≥ 5% of the 115 patients in the 52 mg/m<span class="Sup">2</span>/day dose group (pooled analysis of pediatric patients with ALL and AML). More detailed information and follow-up of certain events is given below.</p>
<table width="100%">
<caption><span>Table 1: Most Commonly Reported (≥ 5% Overall) Adverse Reactions by System Organ Class (N=115 pooled analysis)</span></caption>
<col align="left" valign="bottom" width="25%">
<col align="left" valign="bottom" width="25%">
<col align="center" valign="bottom" width="6%">
<col align="center" valign="bottom" width="8%">
<col align="center" valign="bottom" width="6%">
<col align="center" valign="bottom" width="6%">
<col align="center" valign="bottom" width="6%">
<col align="center" valign="bottom" width="6%">
<col align="center" valign="bottom" width="6%">
<col align="center" valign="bottom" width="6%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="left"></th>
<th align="center"></th>
<th class="Rrule" align="center"></th>
<th class="Botrule Rrule" align="center" colspan="6">Worst NCI Common Terminology Criteria Grade<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</th>
</tr>
<tr>
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="left"></th>
<th class="Botrule Rrule" align="center" colspan="2">ALL/AML (N=115)</th>
<th class="Botrule Rrule" align="center" colspan="2">3</th>
<th class="Botrule Rrule" align="center" colspan="2">4</th>
<th class="Botrule Rrule" align="center" colspan="2">5</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left">System Organ Class<a href="#footnote-1" class="Sup">*</a>
</th>
<th class="Rrule" align="center">Preferred Term<a href="#footnote-1" class="Sup">*</a>
</th>
<th class="Rrule" align="center">N</th>
<th class="Rrule" align="center">%</th>
<th class="Rrule" align="center">N</th>
<th class="Rrule" align="center">%</th>
<th class="Rrule" align="center">N</th>
<th class="Rrule" align="center">%</th>
<th class="Rrule" align="center">N</th>
<th class="Rrule" align="center">%</th>
</tr>
</thead>
<tfoot><tr><td colspan="10" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Patients with more than one preferred term within a SOC are counted only once in the SOC totals. Patients with more than one occurrence of the same preferred term are counted only once within that term and at the highest severity grade.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left" rowspan="2" valign="top">Blood and Lymphatic System Disorders</td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">Febrile neutropenia</span></td>
<td class="Rrule" align="center">63</td>
<td class="Rrule" align="center">55</td>
<td class="Rrule" align="center">59</td>
<td class="Rrule" align="center">51</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" rowspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4161701" conceptname="Pericardial effusion">Pericardial effusion</span></td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span></td>
<td class="Rrule" align="center">40</td>
<td class="Rrule" align="center">35</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" rowspan="9" valign="top"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></td>
<td class="Rrule" align="center">40</td>
<td class="Rrule" align="center">35</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">Abdominal pain upper</span></td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="center">64</td>
<td class="Rrule" align="center">56</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">Gingival or mouth <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></td>
<td class="Rrule" align="center">20</td>
<td class="Rrule" align="center">17</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">84</td>
<td class="Rrule" align="center">73</td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4330466" conceptname="Bleeding from mouth">Oral mucosal petechiae</span></td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="76458" conceptname="Rectal pain">Proctalgia</span></td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span></td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center">90</td>
<td class="Rrule" align="center">78</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" rowspan="8" valign="top">General Disorders and Administration Site Conditions</td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span></td>
<td class="Rrule" align="center">39</td>
<td class="Rrule" align="center">34</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Rrule" align="center">39</td>
<td class="Rrule" align="center">34</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">Irritability</span></td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">Mucosal inflammation</span></td>
<td class="Rrule" align="center">18</td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></td>
<td class="Rrule" align="center">17</td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></td>
<td class="Rrule" align="center">45</td>
<td class="Rrule" align="center">39</td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Hepatobiliary Disorder</td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">Jaundice</span></td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" rowspan="13" valign="top"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">Bacteremia</span></td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candidiasis</span></td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">Catheter related <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">Cellulitis</span></td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">Clostridium <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span></td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">Herpes simplex</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes zoster</span></td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="29735" conceptname="Candidiasis of mouth">Oral candidiasis</span></td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span></td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">Sepsis</span>, including <span class="product-label-link" type="condition" conceptid="196236" conceptname="Septic shock">septic shock</span></td>
<td class="Rrule" align="center">19</td>
<td class="Rrule" align="center">17</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">8</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4327861" conceptname="Bacteremia due to Staphylococcus aureus">Staphylococcal bacteremia</span></td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">Staphylococcal <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span></td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Metabolism and Nutrition Disorders</td>
<td class="Rrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td class="Rrule" align="center" valign="middle">34</td>
<td class="Rrule" align="center" valign="middle">30</td>
<td class="Rrule" align="center" valign="middle">6</td>
<td class="Rrule" align="center" valign="middle">5</td>
<td class="Rrule" align="center" valign="middle">8</td>
<td class="Rrule" align="center" valign="middle">7</td>
<td class="Rrule" align="center" valign="middle">.</td>
<td class="Rrule" align="center" valign="middle">.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" rowspan="5" valign="top">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">Bone pain</span></td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in extremity</span></td>
<td class="Rrule" align="center">34</td>
<td class="Rrule" align="center">30</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top">Neoplasms Benign, Malignant and Unspecified (incl. <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cysts</span> and <span class="product-label-link" type="condition" conceptid="4187628" conceptname="Polyp">polyps</span>)</td>
<td class="Rrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">Tumor lysis syndrome</span></td>
<td class="Rrule" align="center" valign="middle">7</td>
<td class="Rrule" align="center" valign="middle">6</td>
<td class="Rrule" align="center" valign="middle">7</td>
<td class="Rrule" align="center" valign="middle">6</td>
<td class="Rrule" align="center" valign="middle">.</td>
<td class="Rrule" align="center" valign="middle">.</td>
<td class="Rrule" align="center" valign="middle">.</td>
<td class="Rrule" align="center" valign="middle">.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" rowspan="3" valign="top"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center">49</td>
<td class="Rrule" align="center">43</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">Lethargy</span></td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" rowspan="2" valign="top">Psychiatric Disorders</td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span></td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></td>
<td class="Rrule" align="center">24</td>
<td class="Rrule" align="center">21</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Renal and Urinary Disorders</td>
<td class="Rrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">Hematuria</span></td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" rowspan="5" valign="top">Respiratory, Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span></td>
<td class="Rrule" align="center">31</td>
<td class="Rrule" align="center">27</td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">Pleural effusion</span></td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">Respiratory distress</span></td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">Tachypnea</span></td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" rowspan="6" valign="top">Skin and Subcutaneous Tissue Disorders</td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span></td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">Palmar-plantar erythrodysesthesia syndrome</td>
<td class="Rrule" align="center">18</td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">Petechiae</span></td>
<td class="Rrule" align="center">30</td>
<td class="Rrule" align="center">26</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td class="Rrule" align="center">49</td>
<td class="Rrule" align="center">43</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Rrule" align="center">44</td>
<td class="Rrule" align="center">38</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="135618" conceptname="Pruritic rash">Rash pruritic</span></td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" rowspan="3" valign="top"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span></td>
<td class="Rrule" align="center">22</td>
<td class="Rrule" align="center">19</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></td>
<td class="Rrule" align="center">33</td>
<td class="Rrule" align="center">29</td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">.</td>
<td class="Rrule" align="center">.</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1"></a><p></p>
<p class="First">The following less common adverse reactions have been reported in 1–4% of the 115 pediatric patients with ALL or AML:</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span>: </span><span class="product-label-link" type="condition" conceptid="4189378" conceptname="Typhlitis">cecitis</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span></p>
<p><span class="Italics">Hepatobiliary Disorders:</span> <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span>: </span><span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, Enterococcal <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span>, Escherichia <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span>, Escherichia <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span>, <span class="product-label-link" type="condition" conceptid="44784138" conceptname="Sepsis due to fungus">fungal sepsis</span>, <span class="product-label-link" type="condition" conceptid="193120" conceptname="Adenoviral enteritis">gastroenteritis adenovirus</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>, parainfluenza virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="4049965" conceptname="Fungal pneumonia">pneumonia fungal</span>, <span class="product-label-link" type="condition" conceptid="4050869" conceptname="Atypical pneumonia">pneumonia primary atypical</span>, <span class="product-label-link" type="condition" conceptid="437222" conceptname="Respiratory syncytial virus infection">Respiratory syncytial virus infection</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="435459" conceptname="Staphylococcal infectious disease">staphylococcal infection</span></p>
<p><span class="Italics">Investigations: </span>blood creatinine increased</p>
<p><span class="Italics">Psychiatric Disorders: </span>mental status change</p>
<p><span class="Italics">Respiratory, Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorder</span>: </span><span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span></p>
<p>Table 2 lists the incidence of treatment-emergent laboratory abnormalities after Clolar administration at 52 mg/m<span class="Sup">2</span> among pediatric patients with ALL and AML (N=115).</p>
<table width="65%">
<caption><span>Table 2: Incidence of Treatment-Emergent Laboratory Abnormalities after Clolar Administration</span></caption>
<col align="left" valign="top" width="55%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="25%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Parameter</th>
<th class="Rrule" align="left">Any Grade</th>
<th class="Rrule" align="left">Grade 3 or higher</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> (N=114)</td>
<td class="Rrule" align="center">83%</td>
<td class="Rrule" align="center">75%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span> (N=114)</td>
<td class="Rrule" align="center">88%</td>
<td class="Rrule" align="center">88%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">Lymphopenia</span> (N=113)</td>
<td class="Rrule" align="center">82%</td>
<td class="Rrule" align="center">82%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> (N=113)</td>
<td class="Rrule" align="center">64%</td>
<td class="Rrule" align="center">64%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> (N=114)</td>
<td class="Rrule" align="center">81%</td>
<td class="Rrule" align="center">80%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Elevated Creatinine (N=115)</td>
<td class="Rrule" align="center">50%</td>
<td class="Rrule" align="center">8%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Elevated <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> (N=100)</td>
<td class="Rrule" align="center">74%</td>
<td class="Rrule" align="center">36%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Elevated SGPT (N=113)</td>
<td class="Rrule" align="center">81%</td>
<td class="Rrule" align="center">43%</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Elevated Total Bilirubin (N=114)</td>
<td class="Rrule" align="center">45%</td>
<td class="Rrule" align="center">13%</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2	Post-marketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post-approval use of Clolar. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Decisions to include these reactions in labeling are typically based on one or more of the following factors: (1) seriousness of the reaction, (2) reported frequency of the reaction, or (3) strength of causal connection to Clolar.</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span>: <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">Gastrointestinal hemorrhage</span> including fatalities.</li>
<li>Metabolism and nutrition disorders: <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span></li>
<li>Skin and subcutaneous tissue disorders: Occurrences of <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span> (SJS) and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (TEN), including fatal cases, have been reported in patients who were receiving or had recently been treated with Clolar and other medications (e.g., allopurinol or antibiotics) known to cause these syndromes. Other exfoliative conditions have also been reported.</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7. DRUG INTERACTIONS</h1>
<p class="First">No in-vivo drug interaction studies have been conducted [see <span class="Italics"><a href="#S12.3">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8. USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Bold">Pregnancy Category D</span></p>
<p>Clolar (clofarabine) may cause fetal harm when administered to a pregnant woman.</p>
<p>Clofarabine was teratogenic in rats and rabbits. Developmental toxicity (reduced fetal body weight and increased post-implantation loss) and increased incidences of malformations and variations (gross external, soft tissue, skeletal and retarded ossification) were observed in rats receiving 54 mg/m<span class="Sup">2</span>/day (approximately equivalent to the recommended clinical dose on a mg/m<span class="Sup">2</span> basis), and in rabbits receiving 12 mg/m<span class="Sup">2</span>/day (approximately 23% of the recommended clinical dose on a mg/m<span class="Sup">2</span> basis).</p>
<p>There are no adequate and well-controlled studies in pregnant women using clofarabine. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.</p>
<p>Women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with clofarabine. All patients should be advised to use effective contraceptive measures to prevent pregnancy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether clofarabine or its metabolites are excreted in human milk. Because of the potential for tumorigenicity shown for clofarabine in animal studies and the potential for serious adverse reactions, women treated with clofarabine should not nurse. Female patients should be advised to avoid breast-feeding during treatment with Clolar.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness have been established in pediatric patients 1 to 21 years old with relapsed or refractory <span class="product-label-link" type="condition" conceptid="134305" conceptname="Acute lymphoid leukemia">acute lymphoblastic leukemia</span>.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Safety and effectiveness of Clolar has not been established in geriatric patients aged 65 and older.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6	Adults with Hematologic Malignancies</h2>
<p class="First">Safety and effectiveness have not been established in adults.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.7"></a><a name="section-8.6"></a><p></p>
<h2>8.7 	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Reduce the Clolar starting dose by 50% in patients with CrCL of 30 to 60 mL/min. There is insufficient information to make a dosage recommendation in patients with CrCL less than 30 mL/min or in patients on dialysis.</p>
<p>The pharmacokinetics of clofarabine in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and normal renal function were obtained from a population pharmacokinetic analysis of three pediatric and two adult studies. In patients with CrCL 60 to less than 90 mL/min (N = 47) and CrCL 30 to less than 60 mL/min (N = 30), the average AUC of clofarabine increased by 60% and 140%, respectively, compared to patients with normal (N = 66) renal function (CrCL greater than 90 mL/min).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.8"></a><a name="section-8.7"></a><p></p>
<h2>8.8 	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Clolar has not been studied in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10. OVERDOSAGE</h1>
<p class="First">There were no known <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> of Clolar. The highest daily dose administered to a human to date (on a mg/m<span class="Sup">2</span> basis) has been 70 mg/m<span class="Sup">2</span>/day × 5 days (2 pediatric ALL patients). The toxicities included in these 2 patients included Grade 4 <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span>, Grade 2 and 3 <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and Grade 3 <span class="product-label-link" type="condition" conceptid="4083795" conceptname="Maculopapular eruption">maculopapular rash</span>.</p>
<p>In a Phase 1 study of adults with refractory and/or relapsed hematologic malignancies, the recommended pediatric dose of 52 mg/m<span class="Sup">2</span>/day was not tolerated.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11. DESCRIPTION</h1>
<p class="First">Clolar (clofarabine) Injection contains clofarabine, a purine nucleoside metabolic inhibitor. Clolar (1 mg/mL) is supplied in a 20 mL, single-use vial. The 20 mL vial contains 20 mg clofarabine formulated in 20 mL unbuffered normal saline (comprised of Water for Injection, USP, and Sodium Chloride, USP). The pH range of the solution is 4.5 to 7.5. The solution is sterile, clear and practically colorless, and is preservative-free.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12. CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Clofarabine is sequentially metabolized intracellularly to the 5'-monophosphate metabolite by deoxycytidine kinase and mono- and di-phospho-kinases to the active 5'-triphosphate metabolite. Clofarabine has affinity for the activating phosphorylating enzyme, deoxycytidine kinase, equal to or greater than that of the natural substrate, deoxycytidine. Clofarabine inhibits DNA synthesis by decreasing cellular deoxynucleotide triphosphate pools through an inhibitory action on ribonucleotide reductase, and by terminating DNA chain elongation and inhibiting repair through incorporation into the DNA chain by competitive inhibition of DNA polymerases. The affinity of clofarabine triphosphate for these enzymes is similar to or greater than that of deoxyadenosine triphosphate. In preclinical models, clofarabine has demonstrated the ability to inhibit DNA repair by incorporation into the DNA chain during the repair process. Clofarabine 5'-triphosphate also disrupts the integrity of mitochondrial membrane, leading to the release of the pro-apoptotic mitochondrial proteins, cytochrome C and <span class="product-label-link" type="condition" conceptid="4048757" conceptname="Apoptosis">apoptosis</span>-inducing factor, leading to programmed <span class="product-label-link" type="condition" conceptid="4034461" conceptname="Cytolysis">cell death</span>.</p>
<p>Clofarabine is cytotoxic to rapidly proliferating and quiescent cancer cell types <span class="Italics">in vitro</span>.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The population pharmacokinetics of Clolar were studied in 40 pediatric patients aged 2 to 19 years (21 males/19 females) with relapsed or refractory <span class="product-label-link" type="condition" conceptid="134305" conceptname="Acute lymphoid leukemia">acute lymphoblastic leukemia</span> (ALL) or acute myelogenous <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> (AML). At the given 52 mg/m<span class="Sup">2</span> dose, similar concentrations were obtained over a wide range of body surface areas (BSAs). Clofarabine was 47% bound to plasma proteins, predominantly to albumin. Based on non-compartmental analysis, systemic clearance and volume of distribution at steady-state were 28.8 L/h/m<span class="Sup">2</span> and 172 L/m<span class="Sup">2</span>, respectively. The terminal half-life was 5.2 hours. No apparent difference in pharmacokinetics was observed between patients with ALL and AML or between males and females.</p>
<p>No relationship between clofarabine or clofarabine triphosphate exposure and toxicity or response was found in this population.</p>
<p>Based on 24-hour urine collections in the pediatric studies, 49–60% of the dose is excreted in the urine unchanged. <span class="Italics">In vitro</span> studies using isolated human hepatocytes indicate very limited metabolism (0.2%). The pathways of non-hepatic elimination remain unknown.</p>
<div class="Section" data-sectionCode="34073-7">
<a name="section-11.2.1"></a><p></p>
<p class="First"><span class="Italics">Drug-Drug Interactions</span></p>
<p><span class="Italics">In vitro</span> studies suggested that clofarabine undergoes limited metabolism and does not inhibit or induce major CYP enzymes. CYP inhibitors and inducers are unlikely to affect the metabolism of clofarabine. Clofarabine is unlikely to affect the metabolism of CYP substrates. However, no <span class="Italics">in vivo</span> drug interaction studies have been conducted.</p>
<p>An <span class="Italics">in vitro</span> transporter study suggested that clofarabine is a substrate of human transporters OAT1, OAT3, and OCT1. A preclinical study using perfused rat kidney demonstrated that the renal excretion of clofarabine was decreased by cimetidine, an inhibitor of the hOCT2. Although the clinical implications of this finding have not been determined, signs of Clolar toxicity should be monitored when administered with other hOAT1, hOAT3, hOCT1 and hOCT2 substrates or inhibitors.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13. NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Clofarabine has not been tested for carcinogenic potential.</p>
<p>Clofarabine showed clastogenic activity in the <span class="Italics">in vitro </span>mammalian cell chromosome aberration assay (CHO cells) and in the <span class="Italics">in vivo</span> rat micronucleus assay. It did not show evidence of mutagenic activity in the bacterial mutation assay (Ames test).</p>
<p>Studies in mice, rats, and dogs have demonstrated dose-related adverse effects on male reproductive organs. Seminiferous tubule and testicular degeneration and <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> were reported in male mice receiving intraperitoneal (IP) doses of 3 mg/kg/day (9 mg/m<span class="Sup">2</span>/day, approximately 17% of clinical recommended dose on a mg/m<span class="Sup">2</span> basis). The testes of rats receiving 25 mg/kg/day (150 mg/m<span class="Sup">2</span>/day, approximately 3 times the recommended clinical dose on a mg/m<span class="Sup">2</span> basis) in a 6-month IV study had bilateral degeneration of the seminiferous epithelium with retained spermatids and <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> of interstitial cells. In a 6-month IV dog study, cell degeneration of the epididymis and degeneration of the seminiferous epithelium in the testes were observed in dogs receiving 0.375 mg/kg/day (7.5 mg/m<span class="Sup">2</span>/day, approximately 14% of the clinical recommended dose on a mg/m<span class="Sup">2</span> basis). Ovarian <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> or degeneration and uterine mucosal <span class="product-label-link" type="condition" conceptid="4048757" conceptname="Apoptosis">apoptosis</span> were observed in female mice at 75 mg/kg/day (225 mg/m<span class="Sup">2</span>/day, approximately 4-fold of recommended human dose on a mg/m<span class="Sup">2</span> basis), the only dose administered to female mice. The effect on human fertility is unknown.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14. CLINICAL STUDIES</h1>
<p class="First">Seventy-eight (78) pediatric patients with ALL were exposed to Clolar. Seventy (70) of the patients received the recommended pediatric dose of Clolar 52 mg/m<span class="Sup">2</span> daily for 5 days as an intravenous (IV) infusion.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1"></a><p></p>
<p class="First"><span class="Bold">Dose Escalation Study in Pediatric Patients with Hematologic Malignancies</span></p>
<p>The safety and efficacy of Clolar were evaluated in pediatric patients with refractory or relapsed hematologic malignancies in an open-label, dose-escalation, noncomparative study. The starting dose of Clolar was 11.25 mg/m<span class="Sup">2</span>/day IV infusion daily × 5 and escalated to 70 mg/m<span class="Sup">2</span>/day IV infusion daily × 5. This dosing schedule was repeated every 2 to 6 weeks depending on toxicity and response. Nine of 17 ALL patients were treated with Clolar 52 mg/m<span class="Sup">2</span> daily for 5 days. In the 17 ALL patients there were 2 complete remissions (12%) and 2 partial remissions (12%) at varying doses. Dose-limiting toxicities (DLTs) in this study were reversible <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span> and elevated transaminase levels and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, experienced at 70 mg/m<span class="Sup">2</span>. As a result of this study, the recommended dose for subsequent study in pediatric patients was determined to be 52 mg/m<span class="Sup">2</span>/day for 5 days.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.2"></a><p></p>
<p class="First"><span class="Bold">Single-Arm Study in Pediatric ALL</span></p>
<p>Clolar was evaluated in an open-label, single-arm study of 61 pediatric patients with relapsed/refractory ALL. Patients received a dose of 52 mg/m<span class="Sup">2</span> over 2 hours for 5 consecutive days repeated every 2 to 6 weeks for up to 12 cycles. There was no dose escalation in this study.</p>
<p>All patients had disease that had relapsed after and/or was refractory to two or more prior therapies. Most patients, 38/61 (62%), had received &gt; 2 prior regimens and 18/61 (30%) of the patients had undergone at least 1 prior transplant. The median age of the treated patients was 12 years, 61% were male, 39% were female, 44% were Caucasian, 38% were Hispanic, 12% were African-American, 2% were Asian and 5% were Other race.</p>
<p>The overall remission (OR) rate (Complete Remission [CR] + CR in the absence of total platelet recovery [CRp]) was evaluated. CR was defined as no evidence of circulating blasts or extramedullary disease, an M1 bone marrow (≤ 5% blasts), and recovery of peripheral counts [platelets ≥ 100 × 10<span class="Sup">9</span>/L and absolute neutrophil count (ANC) ≥ 1.0 × 10<span class="Sup">9</span>/L]. CRp was defined as meeting all criteria for CR except for recovery of platelet counts to ≥ 100 × 10<span class="Sup">9</span>/L. Partial Response (PR) was also determined, defined as complete disappearance of circulating blasts, an M2 bone marrow (≥ 5% and ≤ 25% blasts), and appearance of normal progenitor cells or an M1 marrow that did not qualify for CR or CRp. Duration of remission was also evaluated. Transplantation rate was not a study endpoint.</p>
<p>Response rates for these studies were determined by an unblinded Independent Response Review Panel (IRRP).</p>
<p>Table 3 summarizes results for the pediatric ALL study. Responses were seen in both pre-B and T-cell immunophenotypes of ALL. The median cumulative dose was 530 mg (range 29–2815 mg) in 1 (41%), 2 (44%) or 3 or more (15%) cycles. The median number of cycles was 2 (range 1–12). The median time between cycles was 28 days with a range of 12 to 55 days.</p>
<table width="75%">
<caption><span>Table 3:  Results in Single-Arm Pediatric ALL</span></caption>
<col align="left" valign="bottom" width="60%">
<col align="center" valign="bottom" width="40%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">N = 61</th>
</tr></thead>
<tfoot>
<tr class="First"><td align="left" colspan="2">CR = Complete response</td></tr>
<tr class="Last"><td align="left" colspan="2">CRp = Complete response without platelet recovery</td></tr>
<tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>Does not include 4 patients who were transplanted (duration of response, including response after transplant, in these 4 patients was 28.6 to 107.7 weeks).</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">  CR %  [95% CI]</td>
<td class="Rrule" align="center">11.5 (4.7, 22.2)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  CRp %  [95% CI]</td>
<td class="Rrule" align="center">8.2 (2.7, 18.1)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Median Duration of CR plus CRp (range in weeks)<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a>
</td>
<td class="Rrule" align="center">10.7 (4.3 to 58.6)</td>
</tr>
</tbody>
</table>
<p>Six (9.8%) patients achieved a PR; the clinical relevance of a PR in this setting is unknown.</p>
<p>Of 35 patients who were refractory to their immediately preceding induction regimen, 6 (17%) achieved a CR or CRp. Of 18 patients who had at least 1 prior hematopoietic stem cell transplant (HSCT), 5 (28%) achieved a CR or CRp.</p>
<p>Among the 12 patients who achieved at least a CRp, 6 patients achieved the best response after 1 cycle of clofarabine, 5 patients required 2 courses and 1 patient achieved a CR after 3 cycles of therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="S15"></a><a name="section-14"></a><p></p>
<h1>15. REFERENCES</h1>
<ol class="Arabic"><li>OSHA Hazardous Drugs. <span class="Italics">OSHA.</span>     http://www.osha.gov/SLTC/hazardousdrugs/index.html.</li></ol>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-15"></a><p></p>
<h1>16. HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Clolar (clofarabine) Injection is supplied in single-use flint vials containing 20 mg of clofarabine in 20 mL of solution. Each box contains one Clolar vial (NDC 0024-5860-01).  The 20mL flint vials contain 20 mL (20 mg) of solution. The pH range of the solution is 4.5 to 7.5.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-15.1"></a><p></p>
<p class="First">Vials containing undiluted Clolar should be stored at 25°C (77°F); excursions permitted to 15 – 30°C (59 – 86°F).</p>
<p>Diluted admixtures may be stored at room temperature, but must be used within 24 hours of preparation.</p>
<p>Procedures for proper handling and disposal should be utilized. Handling and disposal of Clolar should conform to guidelines issued for cytotoxic drugs. Several guidelines on this subject have been published. <span class="Sup">1</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-16"></a><p></p>
<h1>17. PATIENT COUNSELING INFORMATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.1"></a><p></p>
<p class="First"><span class="Italics">Hematologic Toxicity: </span>Advise patients to return for regular blood counts and to report any symptoms associated with hematologic toxicity (such as <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, easy <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>, <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechiae</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) to their physician [see <span class="Italics"><a href="#S5.1">Warnings and Precautions (5.1)</a></span> and <span class="Italics"><a href="#S6.1">Adverse Reactions (6.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.2"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span>: </span>Advise patients of the signs or symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (e.g., <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) and report to the physician immediately if any occur [see <span class="Italics"><a href="#S5.2">Warnings and Precautions (5.2)</a></span> and <span class="Italics"><a href="#S6.1">Adverse Reactions (6.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.3"></a><p></p>
<p class="First"><span class="Italics">Hepatic and Renal Toxicity: </span>Advise patients to avoid medications including over the counter and herbal medications, which may be hepatotoxic or nephrotoxic, during the 5 days of Clolar administration. Also, advise patients of the possibility of developing liver function abnormalities and to immediately report signs or symptoms of <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> [see <span class="Italics"><a href="#S5.6">Warnings and Precautions (5.6) </a><a href="#S5.7">(5.7)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.4"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="434821" conceptname="Systemic inflammatory response syndrome">Systemic Inflammatory Response Syndrome</span> (<span class="product-label-link" type="condition" conceptid="434821" conceptname="Systemic inflammatory response syndrome">SIRS</span>)/<span class="product-label-link" type="condition" conceptid="4227747" conceptname="Capillary leak syndrome">Capillary Leak Syndrome</span>: </span>Advise patients of the signs or symptoms of <span class="product-label-link" type="condition" conceptid="434821" conceptname="Systemic inflammatory response syndrome">SIRS</span>, such as <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">tachypnea</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> and symptoms suggestive of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> [see <span class="Italics"><a href="#S5.4">Warnings and Precautions (5.4)</a></span> and <span class="Italics"><a href="#S6.1">Adverse Reactions (6.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.5"></a><p></p>
<p class="First"><span class="Italics">Pregnancy and Breast-feeding: </span>Advise male and female patients with reproductive potential to use effective contraceptive measures to prevent pregnancy [see <span class="Italics"><a href="#S5.8">Warnings and Precautions (5.8)</a>, <a href="#S8.1">Use in Specific Populations (8.1)</a></span>]. Advise female patients to avoid breast- feeding during Clolar treatment [see <span class="Italics"><a href="#S8.3">Use in Specific Populations (8.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.6"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span>: Advise patients that they may experience <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>,<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and/or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> with Clolar. If these symptoms are significant, they should seek medical attention.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.7"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></span>: Advise patients that they may experience <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> with Clolar. If this symptom is significant, they should seek medical attention.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-17"></a><p></p>
<p class="First"><span class="Bold">Manufactured by: </span><br>Teva Pharmachemie<br>Swensweg 5<br>Haarlem, The Netherlands</p>
<p><span class="Bold">Manufactured for: </span><br>Genzyme Corporation<br>500 Kendall Street<br>Cambridge, MA 02142</p>
<p><span class="Bold">Distributed by: </span><br>sanofi-aventis U.S. LLC<br>Bridgewater, NJ  08807</p>
<p><span class="Bold">www.clolar.com</span><br></p>
<p>©2014 Genzyme Corporation. All rights reserved.</p>
<p>Clolar is a registered trademark of Genzyme Corporation.</p>
<p>Issue date: 17-Sep-2014</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 20 mL Vial Carton</span></p>
<p>NDC 0024-5860-01</p>
<p><span class="Bold Italics">Clolar<span class="Sup">®</span><br>clofarabine injection</span></p>
<p><span class="Bold">Each vial contains<br>20 mg/20 mL (1 mg/mL)</span></p>
<p><span class="Bold">Must Be Diluted Prior<br>To Intravenous Use</span></p>
<p><span class="Bold">Contains 1 (20 mL)<br>Single-Use Vial</span></p>
<p><span class="Bold">genzyme<br>Oncology</span></p>
<p><span class="Bold">Rx ONLY</span></p>
<div class="Figure"><img alt="Principal Display Panel - 20 mL Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=55d3c78b-dca5-436b-97b5-73d166217415&amp;name=clolar-01.jpg"></div>
<br>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CLOLAR 		
					</strong><br><span class="contentTableReg">clofarabine injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0024-5860</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CLOFARABINE</strong> (CLOFARABINE) </td>
<td class="formItem">CLOFARABINE</td>
<td class="formItem">1 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem">9 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0024-5860-01</td>
<td class="formItem">1  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">20 mL in 1 VIAL, SINGLE-USE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021673</td>
<td class="formItem">04/01/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>sanofi-aventis U.S. LLC
							(824676584)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pharmachemie B.V.</td>
<td class="formItem"></td>
<td class="formItem">402108922</td>
<td class="formItem">MANUFACTURE(0024-5860), ANALYSIS(0024-5860), LABEL(0024-5860), PACK(0024-5860)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>43279229-5e81-49e4-8b37-f8f75319ea1b</div>
<div>Set id: 55d3c78b-dca5-436b-97b5-73d166217415</div>
<div>Version: 3</div>
<div>Effective Time: 20140910</div>
</div>
</div> <div class="DistributorName">sanofi-aventis U.S. LLC</div></p>
</body></html>
